Albumin Use After Cardiac Surgery.

Area of Science:

• Critical Care Medicine
• Cardiovascular Surgery
• Clinical Economics

Background:

• Albumin is frequently used in intensive care units (ICUs) post-cardiac surgery.
• The impact of albumin administration on patient outcomes and healthcare expenditure in this population remains debated.

Purpose of the Study:

• To evaluate the association between albumin exposure in the ICU following cardiac surgery and hospital mortality.
• To assess the effect of albumin on post-operative complications and associated healthcare costs.

Main Methods:

• Retrospective, single-center cohort study including adult patients undergoing cardiac surgery.
• Economic evaluation comparing outcomes and costs between patients exposed and not exposed to 4% human albumin in the ICU.
• Statistical analysis adjusted for potential confounders.

Main Results:

• No significant difference in adjusted hospital mortality between albumin-exposed and non-exposed groups (OR, 1.24; 95% CI, 0.56-2.79).
• Albumin-exposed patients experienced higher rates of return to the operating theater for bleeding/tamponade (6.1% vs 2.1%) and received more packed red blood cell transfusions.
• Prolonged ICU and hospital length of stay (18 hr and 87.5 hr differences, respectively) and increased ICU ($2,728) and hospital ($5,427) costs were observed in the albumin-exposed group.

Conclusions:

• Albumin exposure in the ICU after cardiac surgery is not associated with increased hospital mortality.
• Patients receiving albumin exhibited higher illness severity, experienced more complications, and incurred greater healthcare costs.
• A randomized controlled trial is necessary to definitively ascertain the efficacy and safety of albumin in this clinical setting.